Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Bortezomib + Dexamethasone + Lenalidomide |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Bortezomib | Velcade | Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov). | ||
| Dexamethasone | Adexone | Desametasone | ||
| Lenalidomide | Revlimid | IMiD-1 | Revlimid (lenalidomide) is a thalidomide analog which regulates cytokine production and stimulates T cells and NK cells activity (PMID: 24328678). Revlimid (lenalidomide) is FDA approved for use in multiple myeloma, relapsed or refractory Mantle cell lymphoma, and in combination with a rituximab product in follicular lymphoma and marginal zone lymphoma (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05561387 | Phase III | Daratumumab and hyaluronidase-fihj + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Daratumumab and hyaluronidase-fihj Lenalidomide | Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Recruiting | USA | 0 |
| NCT03652064 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Bortezomib + Daratumumab + Dexamethasone + Lenalidomide Dexamethasone + Lenalidomide Daratumumab + Dexamethasone + Lenalidomide | A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy | Active, not recruiting | USA | TUR | POL | NLD | ISR | GBR | FRA | ESP | DEU | CZE | CAN | BRA | 1 |
| NCT02874742 | Phase II | Daratumumab Bortezomib + Dexamethasone + Lenalidomide | Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma | Completed | USA | 0 |
| NCT01668719 | Phase Ib/II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT02441686 | Phase II | Bortezomib + Dexamethasone + Lenalidomide | Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma | Active, not recruiting | USA | 0 |
| NCT06087653 | Phase Ib/II | Bortezomib + Dexamethasone + Lenalidomide | Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM) | Recruiting | USA | 0 |
| NCT05665140 | Phase II | Lenalidomide Isatuximab Bortezomib + Dexamethasone + Lenalidomide | Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients (ELIAS) | Recruiting | DEU | 0 |
| NCT02375555 | Phase II | Elotuzumab Bortezomib + Dexamethasone + Lenalidomide | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | Completed | USA | 0 |
| NCT03729804 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Dexamethasone + Lenalidomide | Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) ((COBRA)) | Active, not recruiting | USA | 0 |
| NCT04268498 | Phase II | Carfilzomib + Dexamethasone + Lenalidomide Bortezomib + Dexamethasone + Lenalidomide Carfilzomib + Daratumumab + Dexamethasone + Lenalidomide | A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma | Recruiting | USA | SWE | 0 |
| NCT04091126 | Phase III | Bortezomib + Dexamethasone + Lenalidomide belantamab mafodotin-blmf + Bortezomib + Dexamethasone + Lenalidomide | Bortezomib, Lenalidomide and Dexamethasone (VRd) With Belantamab Mafodotin Versus VRd Alone in Transplant Ineligible Multiple Myeloma | Recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 1 |
| NCT04923893 | Phase III | Dexamethasone + Lenalidomide Ciltacabtagene autoleucel + Cyclophosphamide + Fludarabine Bortezomib + Dexamethasone + Lenalidomide | A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy (CARTITUDE-5) | Active, not recruiting | USA | SWE | POL | NOR | NLD | ISR | IRL | HUN | GRC | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 3 |
| NCT03319667 | Phase III | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Isatuximab + Lenalidomide Bortezomib + Dexamethasone + Isatuximab + Lenalidomide | Clinical Benefit of SAR650984, Bortezomib, Lenalidomide and Dexamethasone Combination in NDMM Patients Not Eligible for Transplant (IMROZ) | Active, not recruiting | USA | TUR | SWE | POL | NZL | LTU | ITA | GRC | FRA | ESP | DNK | DEU | CZE | BEL | AUS | 6 |
| NCT01208662 | Phase III | Bortezomib + Dexamethasone + Lenalidomide | Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 (DFCI 10-106) | Active, not recruiting | USA | 0 |
| NCT02720510 | Phase II | Panobinostat Bortezomib + Dexamethasone + Lenalidomide | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) | Terminated | USA | 0 |
| NCT03168100 | Phase II | Bortezomib + Dexamethasone + Lenalidomide Dexamethasone + Elotuzumab + Lenalidomide | 2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma | Withdrawn | USA | 0 |
CKB BOOST